Dr. Reddy’s announces the launch of Levofloxacin tablets

Hyderabad, India, June 22, 2011: Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Levofloxacin tablets (250 mg, 500 mg and 750 mg), a bioequivalent generic version of LEVAQUIN^®* tablets in the US market on June 20, 2011, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for Levofloxacin tablets.

The LEVAQUIN^® brand had U.S. sales of approximately $ 1.1 billion for the most recent twelve months ending March 2011 according to IMS Health.

Dr. Reddy’s Levofloxacin tablets 250 mg and 500 mg strengths are available in 50 count bottles and the 750 mg strength is available in 30 count bottles.

Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: www.drreddys.com

*LEVAQUIN^®, is a registered trademark of Daiichi Sankyo Company, Limited.
IMS National Sales Perspectives: Retail and Non-Retail MAT March 2011

For more information please contact:

Media:
S Rajan at rajans@drreddys.com / +91-40- 49002445

Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com / +91-40-66834297
Raghavender R at raghavenderr@drreddys.com / +91-40-49002135
Milan Kalawadia (USA) at mkalawadia@drreddys.com / +1 908-203-4931